AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9007490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.25 mg/kg/12 h
Number of subjects: 10
Study 8024293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical inhaled corticosteroids (beclomethasone dipropionate 400 micrograms daily)
Number of subjects: 15
Study 8024293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3113712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibromomannitol (DBM) at a dose of 4 mg/kg
Number of subjects: 131
Study 3113712 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 131
Study 30017217 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB) group
Number of subjects: 163
Study 30017217 — intervention group
Group type: COMPARATOR
Intervention: No Feedback (NFB) group
Number of subjects: 163
Study 30017217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 163
Study 28374648 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF with 33% dairy protein
Number of subjects: 1272
Study 28374648 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed to receive RUSF)
Number of subjects: 1272
Study 25789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenaline levels
Number of subjects: 163
Study 25789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sE-selectin levels
Number of subjects: 163
Study 25789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin levels
Number of subjects: 163
Study 25789868 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 180-day mortality
Number of subjects: 163
Study 23028103 — intervention group
Group type: EXPERIMENTAL
Intervention: cinacalcet plus low‐dose vitamin D (≤ 6 µg/week of intravenous paricalcitol equivalent)
Number of subjects: 360
Study 23028103 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D sterols alone
Number of subjects: 360
Study 21939609 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assessment after clinical assessment (group A)
Number of subjects: 40
Study 21939609 — intervention group
Group type: COMPARATOR
Intervention: Web-based assessment before clinical assessment (group B)
Number of subjects: 40
Study 19043156 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine-restricted diet
Number of subjects: 2000
Study 19043156 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2000
Study 16774847 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring (n=138)
Number of subjects: 318
Study 16774847 — intervention group
Group type: COMPARATOR
Intervention: Self-selected treatment (n=180)
Number of subjects: 318
Study 15003054 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally modulated Gaussian noise model
Number of subjects: 0
Study 15003054 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling exponent of the correlation sum
Number of subjects: 0
Study 11820714 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient GEMs program (N=79)
Number of subjects: 152
Study 11820714 — intervention group
Group type: COMPARATOR
Intervention: Usual care by family doctors (N=73)
Number of subjects: 152
Study 9539495 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (GP IIb/IIIa blocker), administered as a bolus and 12-hour infusion
Number of subjects: 0
Study 9539495 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (GP IIb/IIIa blocker)
Number of subjects: 0
Study 9539495 — intervention group
Group type: COMPARATOR
Intervention: Low-dose, weight-adjusted heparin regimen, early vascular sheath removal, and elimination of routine postprocedural heparinization
Number of subjects: 0
Study 9539495 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (24-hour preprocedural infusion)
Number of subjects: 0
Study 9539495 — intervention group
Group type: EXPERIMENTAL
Intervention: Other GP IIb/IIIa inhibitors (eptifibatide, lamifiban, tirofiban)
Number of subjects: 0
Study 8299787 — intervention group
Group type: EXPERIMENTAL
Intervention: One intrauterine insemination (IUI) timed 35 hours after ovulatory hCG (Group A)
Number of subjects: 120
Study 8299787 — intervention group
Group type: COMPARATOR
Intervention: Two intrauterine inseminations (IUI) performed 19 and 43 hours after hCG (Group B)
Number of subjects: 120
Study 3405664 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital receipt
Number of subjects: 232
Study 3405664 — intervention group
Group type: COMPARATOR
Intervention: Control (no phenobarbital)
Number of subjects: 232
Study 3405664 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intraventricular hemorrhage
Number of subjects: 232
Study 3405664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecchymoses
Number of subjects: 232
Study 3405664 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight less than 1.0 kg
Number of subjects: 232
Study 31665455 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3 mg SQ daily)
Number of subjects: 40
Study 31665455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29568123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia
Number of subjects: 208
Study 29568123 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthesia
Number of subjects: 208
Study 28069625 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour group structured education programme with follow-up sessions
Number of subjects: 880
Study 28069625 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 880
Study 26806566 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (two sessions of live music-based relaxation exercises)
Number of subjects: 84
Study 26806566 — intervention group
Group type: COMPARATOR
Intervention: Control (listened to a verbal relaxation exercise)
Number of subjects: 84
Study 22842777 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised implementation of the Oral health care Guideline for Older people in Long‐term care Institutions (OGOLI)
Number of subjects: 342
Study 22842777 — intervention group
Group type: COMPARATOR
Intervention: Non-supervised implementation (control group)
Number of subjects: 342
Study 21418359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation
Number of subjects: 100
Study 21418359 — intervention group
Group type: COMPARATOR
Intervention: Bed Rest (Control)
Number of subjects: 100
Study 18678572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led support and education programme (six group meetings over six months)
Number of subjects: 100
Study 16860028 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 40
Study 16860028 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 40
Study 12701987 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic formulation of BNP (nesiritide)
Number of subjects: 0
Study 11045888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan orally at 0700 h
Number of subjects: 12
Study 11045888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan orally at 0700 h and 0100 h
Number of subjects: 12
Study 11045888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan orally at 1300 h
Number of subjects: 12
Study 9075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 40
Study 8370699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g ethanol/kg wt
Number of subjects: 9
Study 8370699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ethanol/kg wt
Number of subjects: 9
Study 8370699 — intervention group
Group type: COMPARATOR
Intervention: 0 g ethanol/kg wt
Number of subjects: 9
Study 3522509 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (3300 mg daily for 12 weeks)
Number of subjects: 55
Study 3522509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31976701 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum states ρ_{1} and ρ_{2} prepared in separate experimental platforms
Number of subjects: 10
Study 31976701 — intervention group
Group type: EXPERIMENTAL
Intervention: Local measurements in randomized product bases
Number of subjects: 10
Study 29917140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy of tamoxifen followed by exemestane
Number of subjects: 4631
Study 29917140 — intervention group
Group type: COMPARATOR
Intervention: Exemestane monotherapy
Number of subjects: 4631
Study 27793138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 108
Study 24020828 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention programme (e-therapeutic platform) for 36 weeks (24 weeks of direct intervention and 12 weeks of follow-up)
Number of subjects: 0
Study 24020828 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol
Number of subjects: 0
Study 22534335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (exercise and diet) for 4 months followed by gastric bypass
Number of subjects: 20
Study 22534335 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up)
Number of subjects: 20
Study 19409657 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole for 10 days
Number of subjects: 161
Study 19409657 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 161
Study 19176089 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTXA) injection into bilateral rectus muscle
Number of subjects: 60
Study 19176089 — intervention group
Group type: COMPARATOR
Intervention: Surgery (recession of bilateral rectus muscle)
Number of subjects: 60
Study 15849388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 100
Study 15849388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 15849388 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study 12807340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum cream (1.5% hyperforin)
Number of subjects: 21
Study 12807340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 21
Study 12807340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum cream
Number of subjects: 21
Study 12807340 — intervention group
Group type: COMPARATOR
Intervention: Hypericum cream and vehicle
Number of subjects: 21
Study 10734287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 0
Study 10734287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1797617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography using a real time, B mode apparatus with a 3.5 MHz lineal transducer
Number of subjects: 3000
Study 6314029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis (Bi HD)
Number of subjects: 10
Study 6314029 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysis (Ac HD)
Number of subjects: 10
Study 30634036 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic BPs
Number of subjects: 510
Study 30634036 — intervention group
Group type: EXPERIMENTAL
Intervention: home BPs
Number of subjects: 510
Study 30634036 — intervention group
Group type: EXPERIMENTAL
Intervention: kiosk BPs
Number of subjects: 510
Study 30634036 — intervention group
Group type: COMPARATOR
Intervention: ABPM
Number of subjects: 510
Study 29381793 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d DHA
Number of subjects: 154
Study 29381793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn and soybean oil)
Number of subjects: 154
Study 26059084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) + aspirin (ASA)
Number of subjects: 222
Study 26059084 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 222
Study 25212644 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 3595
Study 25212644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3595
Study 22374759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (8 oz/day)
Number of subjects: 12
Study 22374759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 12
Study 22374759 — intervention group
Group type: EXPERIMENTAL
Intervention: Punicalagin
Number of subjects: 12
Study 22374759 — intervention group
Group type: COMPARATOR
Intervention: Apple juice (control)
Number of subjects: 12
Study 20673325 — intervention group
Group type: EXPERIMENTAL
Intervention: EDUCORE method (visual learning method with SCORE scores and pamphlet)
Number of subjects: 736
Study 20673325 — intervention group
Group type: COMPARATOR
Intervention: Normal clinical practice (control group)
Number of subjects: 736
Study 17952272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (G1) - 70.5 (45.1‐87.5) units of insulin/day
Number of subjects: 50
Study 17952272 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (G2) - 2 (0.6‐14.1) units of insulin/day
Number of subjects: 50
Study 17952272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (G1)
Number of subjects: 50
Study 17952272 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (G2)
Number of subjects: 50
Study 16365212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (300 microg/m3 particulate concentration)
Number of subjects: 30
Study 16365212 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 30
Study 12549734 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ECG artifact detection and elimination using the energy interval histogram method; applied to EEG recordings.
Number of subjects: 4
Study 11092514 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption (190 mL red wine, 13% vol/vol ethanol, 5 days per week for 10 weeks)
Number of subjects: 20
Study 11092514 — intervention group
Group type: COMPARATOR
Intervention: Abstention from wine for 10 weeks
Number of subjects: 20
Study 9094147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 9094147 — intervention group
Group type: COMPARATOR
Intervention: Control (medicated patients with major affective disorder)
Number of subjects: 14
Study 1531825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120
Study 1531825 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 120
Study 1531825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3893139 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% epinephrine applied twice daily for two weeks
Number of subjects: 100
Study 3893139 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin 25 mg four times daily for one week
Number of subjects: 100
Study 3893139 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of indomethacin treatment in patients receiving topical epinephrine
Number of subjects: 100
Study 31025894 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1.5 g/day)
Number of subjects: 19
Study 31025894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29880209 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized rehabilitation training (Power‐Afa)
Number of subjects: 32
Study 29880209 — intervention group
Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 32
Study 27064493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi group
Number of subjects: 0
Study 27064493 — intervention group
Group type: COMPARATOR
Intervention: Conventional heart group
Number of subjects: 0
Study 24771609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033
Study 24771609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study 22950816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 22950816 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 20865676 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/day in two doses for 60 days)
Number of subjects: 30
Study 20865676 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline (3 g/day in one dose for 60 days)
Number of subjects: 30
Study 19024260 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond self‐etch adhesive with acid etching for 20 seconds
Number of subjects: 125
Study 19024260 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond self‐etch adhesive without acid etching (control)
Number of subjects: 125
Study 15871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg daily (S)
Number of subjects: 2
Study 15871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg daily (F)
Number of subjects: 2
Study 12943890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 12943890 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved and standardized diagnostic imaging
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decision making in surgery and physical/occupational therapy
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: More well-defined indication for surgery considering trauma type, biological age, and functional demands
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: Less stereotyped thinking in follow-up
Number of subjects: 0
Study 10815407 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled randomized trials
Number of subjects: 0
Study 9038665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-drink (early enteral nutrition)
Number of subjects: 60
Study 9038665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1950028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 178
Study 1950028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 3 months
Number of subjects: 178
Study 1950028 — intervention group
Group type: COMPARATOR
Intervention: No antiulcer therapy for 3 months
Number of subjects: 178
Study 1950028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 6 months
Number of subjects: 178
Study 1950028 — intervention group
Group type: COMPARATOR
Intervention: No antiulcer therapy for 6 months
Number of subjects: 178
Study 29954354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulva L.L. extract
Number of subjects: 86
Study 29954354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 26857999 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-based intervention
Number of subjects: 806
Study 26857999 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 806
Study 25304934 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental epidural steroid injections (SESIs)
Number of subjects: 63
Study 25304934 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 63
Study 22552602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed group (n = 145)
Number of subjects: 450
Study 22552602 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal polysaccharide vaccine (MPSV4) in PSV-exposed group (n = 142)
Number of subjects: 450
Study 22552602 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-naïve group (n = 163)
Number of subjects: 450
Study 20377413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20377413 — intervention group
Group type: EXPERIMENTAL
Intervention: 162 mg PRO 140 weekly
Number of subjects: 44
Study 20377413 — intervention group
Group type: EXPERIMENTAL
Intervention: 324 mg PRO 140 biweekly
Number of subjects: 44
Study 20377413 — intervention group
Group type: EXPERIMENTAL
Intervention: 324 mg PRO 140 weekly
Number of subjects: 44
Study 17855125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime2 with a stimulus onset asynchrony (SOA) of 200 ms
Number of subjects: 0
Study 17855125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime2 with a spatial separation of 0 minarc
Number of subjects: 0
Study 17855125 — intervention group
Group type: COMPARATOR
Intervention: Prime2 with a stimulus onset asynchrony (SOA) of 53 ms
Number of subjects: 0
Study 17855125 — intervention group
Group type: COMPARATOR
Intervention: Prime2 with a spatial separation of 58 minarc
Number of subjects: 0
Study 15944071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at acu‐points ST36, LI11, SP10, and GV14
Number of subjects: 10
Study 15944071 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (placebo) treatment
Number of subjects: 10
Study 12627358 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (SBPs) during arterial catheter insertion
Number of subjects: 373
Study 12627358 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (control)
Number of subjects: 373
Study 12627358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 373
Study 10690148 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanging Drop (HD) technique
Number of subjects: 40
Study 10690148 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of Resistance (LOR) technique
Number of subjects: 40
Study 8708726 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with etoposide (120 mg/m2 on days 1 and 3) and vindesine (3 mg/m2 on day 3)
Number of subjects: 84
Study 8708726 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy with ifosfamide, etoposide, and an anthracycline (doxorubicin or epirubicin)
Number of subjects: 84
Study 1914084 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA)
Number of subjects: 89
Study 1914084 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin (CHIP)
Number of subjects: 89